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Abstract 
Evidence-based medicine has instigated a shift in medical paradigms over the 
last decade. Systematic reviews and meta-analyses in particular have a strong 
impact on the way we practice medicine today. Although evidence-based 
medicine focuses on results at an individual patient level, the assumption that 
an increase in the practicing of evidence-based medicine will lead to health 
improvements of the general population seems to be a causal chain. The 
influence of evidence-based medicine is continually extending beyond clinical 
decision- making to act as a foundation for health policy decisions. 
The European Union has realized the potential benefits of evidence-based 
health care. Under the umbrella of thee-Health initiative, the European Union 
plans to implement a telematic (telecommunication and informatics) health 
network by the end of 2004. The objective of this network is to facilitate 
information exchange and to provide databases of the best evidence available 
in health care. Health care providers and the general public will be able to 
access these databases through the internet free of charge. Evaluations of the 
network will have to focus on the extent and depth health care decision makers 
accept, use and apply not only the databases but clinical guidelines as well. 
The only substantial official publication of the EU regarding this program is a 
report by the European Commission on evidence-based health care. The 
document mentions three components to improve evidence-based health care 
in the European Union: (1) Evidence-based medicine; (2) Clinical practice 
guidelines and; (3) Health technology assessment. However, no official 
information about the structure of a telematic health network has become 
available yet. The challenge though is unique - to link 15 different health 
systems with 11 different languages. 
This paper first gives some background information about the practice of 
evidence-based medicine - a description of the status quo; a review of its 
development; and a critical appraisal of its usage - including benefits and risks 
of evidence-based medicine and a detailed look at its influence on health 
policy in general. Next, the paper provides an overview of the health systems 
of the European Union and the political and theoretical framework of a 
telematic health network. Based on these premises, a hypothetical structure of 
evidence-based databases is proposed. This concept takes the heterogeneity of 
the European Union into consideration and examines factors that will be 
crucial for the acceptance of evidence-based databases and clinical practice 
guidelines by health care decision makers. It discusses lessons that could be 
learned from existing databases on national and internationill levels. It also 
describes the necessity of a parallel evaluation program and outlines methods 
of evaluation that could be successfully used to assess the impact and 
effectiveness of the program and provide a base for cybernetic decision -
making. 
5 
L 
~ 
f 
l 
I 
Introduction 
For thousands of years, medicine was an empirically based science- an 
approach with very often amazing results. There was always some kind of a 
"state of the art" in medicine, strongly influenced by ethical and cultural 
backgrounds and consequently very different over time. In the Twentieth 
century the empirical base was gradually replaced by a medicine based on 
clinical trails, which retrospectively seen, often were methodologically flawed. I 
Parallel to these developments was the dramatic increase in the amount of new 
medical knowledge being published every year. About 200,000 biomedical 
articles are released each year- a figure unprecedented in medical history. For 
clinical practitioners and health policy decision makers it has become virtually 
impossible to keep up with this enormous amount of information. A tool is 
needed to prove the effectiveness of medicine and to condense the amount of 
medical information to a manageable format. 
With the emergence of evidence-based medicine, in the form of systematic 
reviews, meta-analyses, and guidelines, such a tool has been created. It 
synthesizes a myriad of medical information from clinical trails and other 
studies into a manageable amount of the current best knowledge of a medical 
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topic. The effectiveness of medicine can now be assessed to a certain extent, 
although this synthesis is not as clear-cut and straightforward as one would 
imagine. 
Controversy still remains about assessment of the quality of studies that have 
been included or excluded. Differing scales may lead to different results1. Also 
the external validity, or generalizability, of the results is mainly a matter of 
l_ 
subjective judgement by the reader. The application of results to an individual 
patient's care may be problematic. Nevertheless, evidence-based medicine 
currently remains the best way to unlock the "truth" about medicine and l 
and health policymakers alike. Evidence-based medicine is an efficient tool for I treatments, and therefore it continues to gain acceptance among practitioners 
keeping clinicians and health policy decision makers informed about the state-
of-the-art solutions for medical problems. 
The need for an efficient tool to assess the effectiveness of medicine has been 
apparent for quite sometime. fu the early 1970's Archie Cochrane, a British 
epidemiologist, published his book " Effectiveness and Efficiency -Random 
Reflections on Health Services". The principles he stresses sound 
straightforward and matter-of-fact, but the subsequent evidence shows that 
they have not been, until recently. Cochrane suggested that medical resources 
should be used to provide those forms of medical treatment that have been 
proven to work in objective evaluations, especially Randomized Controlled 
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Trials. He stressed RCTs as the most effective and reliable source of evaluation 
for medical treatments. 
In 1979 Archie Cochrane wrote," It is surely a great criticism of our profession 
that we have not organized a critical summary, by speciality and subspeciality, 
adapted periodically, of all relevant randomized controlled trials "2 
His propositions were widely acknowledged as very important, but the time 
was not yet ripe. However during the 1980's an international collaboration was 
established to develop the Oxford Database of Perinatal Trials, based on his 
theories. 
li 
In the early 1990's, as the world-wide-web increased in importance and I r 
accessibility, the exchange of information, especially medical information, 
reached new dimensions. Efficient information technologies seemed to have 
been the missing link for a successful international launch of evidence-based 
medicine. Databases of clinical trials and articles were established and made 
available online. Literature research switched from the library and the manual 
search of medical books and journals to the personal computer and an 
unprecedented availability of medical information online. 
In 1992, four years after Archie Cochrane had died, the Cochrane Center in 
Oxford, UK was founded and one year later the Cochrane Collaboration was 
established, dedicated to the synthesis of evidence-based medicine. 
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Ten years later systematic reviews and meta-analyses increasingly meet the 
needs of practicing physicians. The overwhelming amount of published 
medical literature and clinical trials is synthesized into evidence-based "best 
practice" guidelines or provided as systematic reviews or meta-analyses by a 
variety of institutions. Health policy and political decision makers realize that 
the expectation of" best practice" should be more than depending on the 
subjective initiative of clinicians. If best practice is to be a right of every 
patient, political measures have to be put forth to make that reality. A 
technological infrastructure has to be established to make evidence-based 
medicine available in a quick, easy and reliable way for all physicians and 
health policy decision makers. Evidence-based medical facts offer a great 
resource for making medicine and health systems more efficient with a better 
outcome for the patient and lower costs for the health system. 
The European Union faces a special challenge. 15 different nations with 15 
different health systems and II different languages have the potential to be 
connected to an information network without harmonizing the health systems. 
Programs have been developed and firsts steps have been taken, but the 
challenge is unique, because of the heterogeneity of the task. 
All European health systems are either national health care systems or are 
based on widely available health funds that are more or less subsidized by the 
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governments. The prime objective for the European Union remains an 
improvement of population health as a result of the use of all valid and relevant 
information gained through evidence-based medicine and the monitoring of 
health outcomes. The improvement of the cost effectiveness of the various 
health systems would be a very welcome side effect, even if not officially 
outlined as an objective. In 1999 the European Union started a program called 
e-Europe. This program is considered a political initiative by the European 
Commission to ensure that the EU and its citizens are prepared for the 
challenges and changes an emerging information society is bringing. Key 
objectives of e-Europe are bringing every citizen and institution in the EU 
online, creating information networks for an efficient exchange of knowledge I 
r and information and ensuring that these processes are socially inclusive
3
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One part of e-Europe is e-health. Under the above-mentioned premises, e-
health should improve the quality of health care of European citizens in the 
future. The challenge is unique: as previously noted, 15 different countries 
have 15 different health systems that are culturally grown and all reflect some 
kind of national philosophy towards health care. Article 29 of the European 
Union Treaty rules out a harmonization of health systems in Europe. One of 
the main goals is the implementation of a telematic (telecommunication and 
informatics) health network for all European health professionals and health 
policy decision makers to provide the infrastructure for evidence-based 
prevention, diagnosis, and treatment, under the title of evidence-based health 
10 
care. The telematic health network will combine two closely related health care 
realms: information and communication. 
Communication in this case is the exchange of information facilitated by the 
tools of modern technology such as Internet databases of evidence- based 
medicine and chip cards of patient medical information. E-health, for example, 
is currently conducting a program to distribute such patient data cards called 
"health smart cards." Family physicians issue credit-card sized cards to each of 
their patients. The cards have microchips that contain the relevant medical 
history and data for the individual patients. When a patient visits various 
doctors, hospitals or clinics, he or she simply takes along the health card. 
Medical personnel can readily access patient data and new information can be 
added. A doctor can be alerted if a new prescription does not combine with one 
the patient is already taking. Emergency rooms can see a person's blood type, 
medical conditions, medical history, all at a click of the mouse. 
The future network will not only make it easier for health care providers to 
access patient information, it will also ease the access to the newest studies, 
treatments and clinical practice guidelines. European-wide databases will make 
data on successful treatments in England available to doctors in Germany. 
Information on all kinds of diseases and treatments can be readily found in one 
place. Such information sharing will be faster, easier, less expensive and more 
up-to-date than the traditional methods of medical journals and texts. 
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A document reported to the European Commission by Perleth eta!. in 1999, 
developed a theoretical framework for categorizing different parts of health 
research and information gained through evidence-based medicine4• The 
authors see three components of "best practice" that will create a base for 
evidence-based health care: 
• Health Technology Assessment 
• Evidence Based Medicine 
• Clinical Practice Guidelines 
The report does not deal with how a telematic health network could be 
established practically. The concepts upon which these databases will be 
structured, and what the contents will be are rather vague. No official 
documents are currently available that deal with this topic. 
Consideration of this has caused me to examine the possible advantages and 
limits of evidence- based databases in a European telematic health network. 
Since no official European documents exist about the form and concepts of this 
database, the approach will be mainly a hypothetical one, based on literature 
research and existing paradigms used on national levels. 
In this master paper, I will first draw a brief overview of the status quo of 
evidence- based medicine and how it is developed. Evidence-based medicine 
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has led to a shift in what is viewed as best practice in the past decade and 
changed paradigms in medicine in almost an unprecedented way. I will outline 
the formation of evidence-based medicine and critically appraise the pros and 
cons of evidence-based practice and its influence on health policy. 
In the second part of my paper, I will give an overview of the European health 
systems, their differences, and the legislative background of the European L 
Union treaties regarding health systems. I will outline how an evidence-based 
information database could be implemented and how this could affect an 
, 
improvement in the efficiencies of health systems and health outcomes. 
I Possible obstacles, like technological, political, economic, and legal limitations will be considered as well. Clinical practice guidelines will definitely play a 
key role in this health network. I will have a close look at practice guidelines 
and factors that increase their acceptance among health decision-makers, 
particularly in the European Union. 
Finally I will outline a concept for an evaluation program that can support and 
guide the successful implementation of a European telematic health network. I 
will look at different forms of evaluation and how they could be used 
considering the heterogeneity of the European health systems, the political 
varieties, and multinational backgrounds of EU members. 
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Evidence- based medicine breaking the borders 
Throughout history physicians have always based their medical practices on 
some type of evidence. Such evidence could have been grounded on narratives, 
expert opinions, experience, or religious revelations, and, in the 20 Century, 
clinical trials. Medicine is an art, changing with time and knowledge. 
Physicians are expected to practice lege artis - meaning in accordance with the 
current best evidence and the consensus of medical society. This is true, even 
though that which may be considered the best treatment today may not be so 
tomorrow or may even vary from one country to another.5 
Evidence-based medicine evaluates whether or not treatments are effective and 
to what extent. In particular, systematic reviews and meta-analyses have 
brought a new level to quality of care into many fields of clinical medicine. An 
example of such success has been the changes induced in the usage of 
corticosteroids and premature babies. 6 In 1972 the first randomized controlled 
trial showed an improved outcome for premature babies by administering 
corticosteroids to mothers about to go into premature labor. A decade later 6 
additional studies showed similar results. However, most obstetricians did not 
become aware of this fact until 1989, 17 years after the first study, when a 
systematic review was published. This review reported how the odds of dying 
from complications of immaturity were reduced by 30 to 50% for a premature 
baby whose mother was administered an inexpensive course of corticosteroids. 
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As a result of this systematic review, the administration of corticosteroids for 
women at risk to having premature births has become a gold-standard-
treatment worldwide. 
Tens of thousands more babies could have survived had a systematic review 
been conducted 10 years earlier. Today the logo of the Cochrane Collaboration 
illustrates the results of a hypothetical systematic review done with the first 7 
studies that were conducted on corticosteroid use and premature babies. These 
results would have shown a clear benefit of the treatment had a systematic 
review been conducted years earlier. 
Evidence-based medicine probably would not have progressed to such a great 
extent in clinical medicine without the global expansion of Internet use during 
the last decade. Evidence-based medicine is taking advantage of the speed and 
ease of the Internet to spread and share medical information in a manner that 
truly is breaking borders. The databases of the Cochrane library are an 
impressive example. Physicians and scientists from around the world develop 
evidence-based reviews on pertinent clinical topics. The results can be viewed 
from any personal computer with Internet access. Internet access, however, 
remains a critical factor. E-Europe and its programs are striving to promote 
Internet use. Once the adoption of the Internet in the health care sector reaches 
a critical mass, progress will rapidly advance. This phenomenon has already 
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taken place years ago in other technological fields such as the telephone, the 
CD and the computer.7 
In one decade evidence-based medicine has changed the way clinical medicine 
is practiced. Systematic reviews not only influence clinical decisions but 
increasingly health policy. Following the initial enthusiasm, the discussion 
about the use of scientific evidence has become more stratified and the 
boundaries of evidence-based medicine are more evident today. Still, many 
questions remain and the differences between the chances and limits are often 
a matter of a subjective viewpoint. 
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The boundaries of evidence-based medicine- the chances 
When evidence-based medicine evolved in the early 1990's, it initiated a 
paradigm shift in clinical decision- making8 Until then the majority of 
physicians depended mainly on opinion-based information for best practice. 
Medical best practice was more or less authoritatively defined and distributed 
by leading clinical members ofthe medical society and experts in their fields. 
Their opinions were generally supported by clinical trials and experience. 
Evidence-based medicine started to question ostensibly high quality evidence. 
The methodologies and generalizabilities of clinical trials were critically 
appraised, and a hierarchy of the strengths of research-based evidence was 
developed. The importance of beneficial changes in morbidity and mortality 
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outcomes versus pathophysiologic changes was emphasized. By and large, 
evidence-based medicine stated that intuition, unsystematic clinical approach 
and personal opinion are insufficient grounds for clinical decision-making, and 
therefore it places a lower value on authority than the traditional medical 
paradigm.9 
Evidence-based medicine focuses explicitly on the application of valid 
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research concerning clinical treatment of individual patients. Its rationale is 
strictly quantitative, this can be a strength but also a weakness. The strength 
lies in an approach to see evidence-based medicine as only one factor in the 
complex process of clinical decision- making at the individual level. i 
Experience, psychosocial conditions, and patient values are all additional and 
at least equally important factors that contribute to the decision process in 
which the best evidence is applied. However they should not be the sole 
determinants either. Evidence-based medicine can provide the quantitative, 
scientific framework. Human decision-making is a complex process in daily 
life as well as in clinical settings. What Schulkin calls decision-sciences 
identify the underlying value of a decision determined by the analysis of 
consequences and the probability that a particular decision is correct or 
incorrect.10 In addition various kinds of inherent biases are crucial factors that 
influence such decisions. For example Schulkin also states that" omission bias 
is the tendency not to do something that could cause hann, and naturalistic 
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bias is the view that natural things do less harm than man-made things. " 11 
Evidence-based medicine can help to minimize the influence of some biases 
and help evaluate the consequences of decisions. In a health care world of 
limited resources, it is important to determine which interventions work best. 
This helps health care decision-makers to focus on effective interventions. Any 
discrepancy between what is emphasized and what works best will 
compromise health outcomes. 12 
. 
Evidence-based medicine in the forms of systematic reviews or guidelines, 
offers a time saving tool to clinical decision-makers, who can not possibly 
I keep up with and critically appraise the tremendous amount of new medical information. This so-called preprocessed evidence meets the needs for 
information about current scientific evidence in an efficient way. 
The boundaries of evidence-based medicine- the limits 
One limiting factor that can be an advantage of evidence-based medicine has 
already been mentioned herein. The rationale is a strictly quantitative one. 
Critics say that this will lead to the emergence of a new utilitarian orthodoxy.13 
The danger certainly exists, but it is worth mentioning that lack of evidence 
does not necessarily equate to lack of effectiveness. Immeasurable or 
unmeasured factors such as empathy and psychosocial aspects might be crucial 
for the success of an evidence-based therapy. In a world where psychosomatic 
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diseases increase, a holistic approach seems to become increasingly important. 
Too much emphasis on evidence-based medicine neglects the complex, 
interpersonal matter of clinical care. Therefore evidence-based medicine 
should remain just a tool in clinical decision making, it's not a reflection of the 
truth. Research can only provide best current evidence but never absolute 
certainty. Karl Popper, one of the most influential philosophers of the last 
century wrote, " Science is the search for truth; and it is very possible that 
some of our theories are indeed true. But even if they are true we can never 
know that for certain. "14 
Another point of critique is what is considered the highest quality of evidence. 
Randomized controlled trials are the gold standard in many hierarchies of 
evidence. RCTs try to minimize bias through strict methodological criteria and 
a clearly defined outcome of interest. Yet a high internal validity does not 
necessarily mean a high external validity. The strictly selected study 
populations might be very different from the heterogeneous, co-morbid 
population of daily clinical practice. Criteria that guarantee high internal 
validity often conflict with those for external validity. Older patients and 
women are often underrepresented and patients with co-morbidities are 
frequently excluded from the study population. Therefore, generalizability can 
be problematic, and the external validity of study results must be evaluated for 
each single patient by the treating physician. 
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Some authors demand that for externally valid evidence we need "medicine-
based" studies that include, not ignore, medical reality. 15 Although RCTs are 
an ideal design for interventional studies, results rarely reflect the magnitude of 
possible harms. Observational studies on the other can provide us with 
information that RCTs do not reflect. Observational studies are a better tool to 
assess harms and prognosis, but still they are ranked lower in the hierarchy of 
evidence because they are more prone for bias. Nevertheless reducing 
scientific evidence to RCTs alone could cause us to overlook very important 
aspects of medicine and health care. 
Moreover, critical appraisal is especially important in a field where the results 
of a single trial can trigger enormous financial gains or losses for 
pharmaceutical companies. Monetary interests underlie most trials, so the 
importance of monetary benefits may supercede health care priorities. 16 Yet, 
critical appraisal relies on the knowledge and consensus on high quality of 
scientific evidence- what it is and what it is not. Even this basic question is 
still a matter of debate. 
The hierarchy of the evidence 
The core of evidence-based medicine consists of clinical studies and trials. In 
the search for the "best evidence", however, quality criteria are commonly 
applied. The pursuit of quality criteria is founded in the belief that the manner 
in which studies and trials are designed and conducted correlates to the 
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likelihood that the results reflect the "truth" .17 As systematic reviews and meta-
analyses become increasingly important in evidence-based medicine, the issue 
of quality assessment gains significance. Systematic reviews use a 
comprehensive review of literature, focusing on a clinical question as their 
base. Health analysts must first critically appraise the quality and applicability 
of scientific evidence retrieved during literature reviews. 
How "quality" is defined in studies and clinical trials is still a matter of debate. 
Numerous quality-rating scales have been published with more than 60 grading 
scales identified. 18 The approaches vary in how they weigh efficacy versus 
effectiveness.19 Well-known institutions working on these tasks include the 
Canadian Task Force on Periodic Health Examination, the Cochrane 
Collaboration, and the U.S. Preventive Services Task Force (USPSTF). The 
later has developed a hierarchy of evidence that has been widely adopted 
internationally for use in systematic reviews: 
U.S. Preventive Services Task Force Evidence Codes: 
I Evidence obtained from at least one properly designed randomized 
controlled trial. 
11-1 Evidence obtained from well-designed controlled trials without 
randomization. 
11-2 Evidence obtained from well-designed cohort or case--control analytic 
studies, preferably from more than one center or research group. 
11-3 Evidence obtained from multiple time series with or without the 
intervention. Dramatic results in uncontrolled experiments 
111 Opinions of respected authorities, based on clinical experience, 
descriptive studies or reports of expert committees. 
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The USPSTF evidence codes are based on the rationale that Randomized 
Control Trials (RCTs) minimize systematic bias and therefore rank at the top. 
On the other hand, expert opinions, the bases of clinical decisions over 
decades, rank lowest. Nevertheless, some health analysts argue that a 
methodological viewpoint alone provides an incomplete description of 
quality20. Woolf eta!. have concluded that the strength of the evidence also 
depends on factors such as consistency of findings across studies and 
emphasize that RCTs may not always be the "gold standard". For example, 
observational studies, like prospective cohort studies, prov'..:l.e more 
information on effectiveness in terms of health outcomes than RCTs. 
Furthermore, meta-analyses and systematic reviews would have to be ranked I 
higher than a single RCT, because they combine the results of single studies. 
Each of these single studies might have certain systematic or random errors 
that affect their results. By summarizing and pooling the results, the errors are 
minimized and weigh less in the combined result. 
Two articles in the New England Journal of Medicine have also challenged the 
common hierarchy of evidence. Benson et a!. compared the .results of 
observational studies with those of randomized controlled trials.21 In seventeen 
of nineteen &'1alyses of combined treatment effects, estimates of the magnitude 
of results of observational studies were within the 95% confidence interval of 
the combined magnitude of results of randomized controlled trials. These 
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findings foster a common criticism that well-designed obsetvational studies are 
underrated in the USPSTF evidence codes. Concato, et a!. arrived at a similar 
conclusion by comparing the results of observational studies with the 95% 
confidence intervals of meta-analyses of randomized clinical trials.22 The 
authors summarize that the results of well-conducted observational studies do 
not systematically overestimate the magnitude of the effects of treatments. 
To increase a reader's understanding of the results of randomized controlled 
trials, the design and methods used in the trials must be transparent. The 
CONSORT (Consolidated Standards of Reporting Trials) statement strives to 
improve the reporting standards of RCTs?3 This statement outlines how trials 
should be reported in publications and provides a checklist and flow diagram 
to accomplish this goal. Clear specifications on methods, results, and 
discussions of trial conclusions in articles should ease the critical appraisal 
process of trials. The QUORUM (Quality of Reporting of Meta-analyses) has a 
similar rationale regarding publication standards of meta-analyses.24 
As mentioned, high quality methodology in designing and conducting studies 
is crucial in avoiding both systematic and unsystematic bias. On the other 
hand, the relevance of assessments apart from the methodology of a study, 
though harder to define, is also essential. Such assessments reveal whether or 
not a study is clinically significant or policy relevant.25 The applicability of 
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results on a larger population is ultimately one of the most important factors in 
systematic reviews. 
Finally, assessing the quality of studies is a subjective process. Even when 
quality criteria are uniformly accepted they may be inconsistently applied. A 
report on pharmacological agents in alcohol dependence showed that the 
reviewer's background affected the quality ratings.26 Ratings given by clinician 
tended to be higher than those given by methods experts. Therefore, if a 
systematic review has more than one analyst, all analysts must review all the 
articles to avoid differential bias. An interesting research question would also 
I be if a "nationality bias" exists in rating the quality of studies. For example are results of German reviewers different from results of their English 
counterparts? 
The issue of grading articles as inputs into evidence-based medicine is 
complex. Future research will be necessary to make grading systems 
themselves more evidence-based. 27 Grading literature must become reliable 
and reproducible. The applicability of the results must be valid and useful. 
Such standards will combine to increase the quality of evidence-based 
medicine. 
The floating borders between chances and limits of evidence-based medicine 
and the intense discussion about the hierarchy and quality of scientific 
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evidence show that clinical practice guidelines and evidence-based databases 
are at the status of a constant "work in progress". A fact a telematic health 
network will have to take into consideration. 
As mentioned above, e-health was founded as a political initiative with the 
objective to improve health care in the European Union. One effect that an 
increased emphasis on evidence-based medicine will have in the European 
Union in addition to this objective is an increased influence of evidence-based 
facts on health policy. 
Evidence-based medicine and health policy I 
' 
Because evidence-based medicine used in clinical decision-making focuses on 
the health problems of individual patients its impact on health outcomes 
remains rather small compared to the potential impact of policy changes. Life 
expectancy, morbidity, mortality, DALYs (disability adjusted life years) and 
QUAL Ys (quality adjusted life years) on a population level can be best 
improved by policy decisions that affect clinical decisions very broadly or 
improve public health measures for sizable populations. This can be through 
direct implementation of programs, like primary or secondary preventive r 
measures, or through the erection of an infrastructure that fosters improved 
clinical practice. An example would be the fostering of evidence-based 
practice through the provision of evidence-based databases, clinical practice 
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guidelines, and a functioning infrastructure enabling widespread access by 
practicing clinicians. 
Noting the increasing success of evidence-based medicine in clinical practice, 
some health care professionals demand the incorporation of evidence-based 
knowledge into health policy decision-making and public health.28 
Information gained from evidence-based medicine is already used by health 
insurance coverage decisions.29 Although it is not clear such an approach helps 
to reduce costs, it can help to direct medical resources towards more effective 
health care. Besides health insurance, it is unclear to what extent evidence-
that the influence over media might be indirect since findings in systematic I r based medicine influence health policy decisions. Some health analysts suspect 
reviews have higher media coverage than single studies?0 
Others see a demand that goes beyond the use of data already available. 
Heller, a British epidemiologist, suggests the development of a counterpart to 
evidence-based medicine called "Evidence for Population Health"?1 He states 
that evidence-based medicine lacks population perspective and demands the 
creation of methodologies that have special relevance to public health. 
On the other hand, some experts argue tbat systematic reviews could already 
be the ideal tool for policy makers and consumers as adjuncts to decision-
making.32 Although systematic reviews usually do not focus on health 
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outcomes on population levels, they reflect the intermediate: outcomes on an 
individual level. Information gained through systematic reviews could be 
utilized to address two of the main concerns of health policy: 
• Costs 
• Quality of health care 
For both topics, results from systematic reviews and meta-analyses as 
intermediate findings could probably extrapolate on the population level in 
many cases. In particular meta-analyses can reflect the effectiveness of 
intervention on broader scale. 
Costs 
Financial health care resources are limited and must be allocated in a way that 
achieves the maximum benefit for the population. Health care systems are 
confronted with increasing costs throughout the Western world. People 
accountable for managing these health care systems must decide what types of 
services will be covered - not only diagnostic, interventionai, and therapeutic 
procedures, but also primary and secondary preventive measures. As a recently 
published article in Lancet illustrates, even a well established preventive 
measure like screening for breast cancer with mammography suddenly lacks 
scientific evidence after the underlying clinical studies show strong 
methodological flaws?3 In fact, the risks associated with mammographies may 
even outweigh potential benefits in certain age groups. Consequently, health 
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care officials in Switzerland are reconsidering patient reimbursement for 
mammographies. 
Clinical preventive services (screening. counseling, immunizations, and 
chemoprevention) can be an enormous waste of financial resources, if not 
evidence based, since they represent major investments in the future health of 
large populations?4 Cost-effectiveness analysis compares expected benefits, 
risks and costs of alternative strategies and is a valuable tool to bring economic 
aspects into consideration. 
Quality of care 
Lohr defines quality of care as " the degree to which health services for 
individuals and populations increase the likelihood of desired health outcomes 
and are consistent with current professional knowledge".35 Ultimately, 
"quality of care" means the outcome that patients experience and this is often, 
in tum, related to cost. This relationship stems from factors that strongly 
influence the quality of care: overuse, under-use, and misuse of health care?6 
Overuse occurs when inappropriate and unnecessary care is administered, 
under-use is the lack of appropriate and needed care, and misuse stems from 
poor technical or personal performance of health care professionals. All three 
ultimately increase costs. High quality of care also takes factors such as patient 
values and preferences into consideration. Evidence-based medicine, per se, 
does not consider such aspects. The use of decision analysis based on findings 
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of evidence-based medicine, could increase the consideration of patient 
preferences and values, which should be a significant factor in long-term 
health policy planning. 37 
Although evidence-based medicine can offer a lot to policymakers, it should 
not be the sole base for decision-making. Values and societal expectations 
must be considered as well. Greater reliance on scientific evidence and a 
systematic approach in decision making could lead to improved health policies. 
Health care participants must learn to use evidence-based medicine and must 
be able to distinguish between narrative and systematic reviews. Woolf 
proposes a bibliographic evidence collection center with simulation modeling I programs?8 The models import evidence-based data from databases and 
incorporate complex patient data to conduct sensitivity analyses from different 
perspectives (e.g. deaths, cost-effectiveness ratio, quality adjusted life 
expectancy). Such analysis would have great value for clinicians and 
policymakers and could be used for a more rational resource allocation. Woolf 
uses the example that evidence-based primary preventions such as exercising, 
not -smoking, lowering cholesterol and controlling blood pressure can prevent 
more deaths per year than evidence-based treatments for cardiovascular 
diseases. Thus, he detects a mismatch in priorities since most of the US 
expenditures in health are geared towards treatments. 
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Using scientific evidence under these premises could open new perspectives 
for health policy and health care. Systematic reviews can summarize large 
amounts of data and highlight gaps in scientific evidence. 
Information for policy makers in the form of evidence-based medicine could 
provide a strong base. Cultural, philosophical, and ideological factors play 
other key roles in decision- making, but vary from nation to nation. The 
L 
European Union with its heterogeneous cultures and differing health care 
systems are a paradigm. 
I 
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The European Health Systems 
The European Union does not have a universal health care system. Each of the 
15 EU member states' health care systems is unique and nationally grown. 
Specific political, historical and cultural traditions have influenced the 
development. As a result, the health care systems of the member states differ 
considerably. There are three predominant types of health care finance in the 
European Union. The first is publicly financed by general taxation (e.g. Italy, 
Sweden, United Kingdom). The second is based on a compulsory social 
insurance operating with social insurance funds. These funds may be 
independent from the government but are usually subsidized by the 
government in years of deficit (e.g. Austria, France, Germany). The third is 
privately financed in the form of additional health insurances on a voluntary, 
supplemental base. These private insurance policies pay for single rooms in 
hospitals; treatments that are usually not covered by compulsory insurances 
like acupuncture or homeopathy, and provide additional fees for the treating 
physicians. 
The European Parliament has provided for a comparative study of the 
European health systems. 
In essence, the fifteen health care systems in the EU reflect a 
variety of different philosophies and approaches and retain 
their own peculiarities .... Each system has its own strengths 
and weaknesses and none of the systems provide a wholly 
31 
L 
~---
L 
successful solution. Hence, each has to learn from the 
experience of the other fourteen. 39 
Health policy mainly remains a national matter and is guided by the subsidiary 
principle. Article 29 ofthe European Union Treaty specifically excludes the 
harmonization of national health laws. 
Nevertheless a "silent" harmonization of the European health systems is taking 
place. The 1991 Maastricht Treaty has not only eased travel within the 
European Union through the elimination of border controls but has also created 
more competencies for the European Union in public health. The European 
Commission has started to develop specific policies in public health fields with 
high priorities, such as AIDS, tobacco and alcohol abuse, and environmental 
causes of illness. In relation to these public health issues, the member states 
believe that the European Union can introduce legislation to coordinate the 
problem approach more efficiently and more effectively. The 1997 Treaty of 
Amsterdam provides an even stronger legal basis for public health 
legislation.40 Besides the legal aspects, the approval of new drugs has been an 
agenda of the European Union for a couple years, entirely replacing national 
drug approvals. 
A report of the Center for Tobacco Control Research and Education of the 
University of California, San Francisco illustrates that a common legislation, 
however, can also have its down sides.41 In 1998, the European Union adopted 
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a directive restricting, and later ending, tobacco advertising and sponsorships 
in the European Union. In 2001, however, Germany fought the directive before 
the European Court of Justice and successfully had it annulled. Once secret 
tobacco documents reveal how the tobacco industry lobbied German and 
Dutch politicians to defeat the directive and subsequently influence tobacco 
policy in all of the 15 member states. 
A single European market, unified legislation, and an increase in migration in a 
Europe without borders, bring forth new challenges in the field of public 
health. Two rulings of the European Court of Justice in 1998 imply that health 
I 
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care goes beyond national borders and is subject to European laws on the free 
movement of people and services according to the Maastricht Treaty. 
Therefore, national insurance agencies are generally required to cover the costs 
for the fees of all health care services rendered within a com, try of the 
European Union to a European Union citizen. What is convenient for sick 
travelers can also lead to political tensions in other fields. An example of this 
can be found in the different abortion laws in Portugal and Spain. Abortion is 
illegal in Portugal. A Portuguese woman who wants to have the procedure can, 
however, travel to Spain to have it done. She can then file a claim to have her 
Portuguese health insurance cover the costs as long as she is able to prove that 
the abortion was due to medical reasons. Conservative groups in Portugal are 
active against these circumventions of Portuguese law. 
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Although all major health policy decisions will still be handled on a national 
level, a convergence of policies and new routes of exchange in medical 
know ledge, medical technologies and health service know-how will be the 
focus and challenges of the new century. In April2001 the European 
Parliament voted for a renewed attempt to extend the European Union's 
influence over national health policies. The Parliament seeks to establish a 
European Health Coordination and Monitoring Center over the next 5 years. 
Especially with the emergence of the Internet and other information 
technologies, new opportunities for improvements in effective and efficient use 
of medical knowledge and information are apparent. 
The European Union started a program called "e-Europe" in December 1999. 
It is a political initiative aimed at accelerating Europe's transformation into an 
information society. E- Europe uses the World Wide Web as a new medium to 
create an information and interaction base for European citizens with the 
European government and EU institutions. Furthermore, e-Europe promotes 
Internet access for all European citizens and the creation of an information 
network - especially in the fields of health and business. 
E-Europe consists of various initiatives such as e-Commerce, e- Education and 
among others, e-Health. In front of a special European Council meeting in 
Lisbon in March 2000, the European Commission published a statement on the 
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future concepts and visions of e-Europe42. The chapter one-Health takes a 
closer look at the status quo of the relationships between health care systems, 
costs and the use of new communication technologies. 
Digital technologies can improve the productivity and scope of 
health care. This potential is not being fully exploited - only 1 
% of total health spending is used on information technology. In 
summery, secure services have to be developed linking 
hospitals, pharmacies, primary care centers and homes of 
people. Fragmented health markets in the EU also hamper 
innovation and the spread of best practice.43 
The Commission explicitly mentions that the goal is not a harmonization of 
health care systems at a European level that would conflict with Article 29 of 
the European Union Treaty. The Commission instead lists some innovative 
targets for the future. Two of them are particularly interesting and closely 
relate to the use of evidence-based medical knowledge and information 
technology. The targets by the end of 2004 include: 
All health professionals and managers should be 
linked to a telematic health infrastructure for 
prevention, diagnosis and treatment. The 
priorities agreed for a number of key pan-
European medical libraries-on-line and health 
care expertise centers to be operational by the 
end of2004.44 
The WHO defines three intrinsic goals of health systems: improving health, 
increasing responsiveness to legitimate demands of the population, and fair 
distribution of financial burdens. The WHO measured the performance of 
individual countries in view of resources available.45 In overall performance of 
health systems, the WHO ranks 13 of the 15 European Union member states in 
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the top 25 systems worldwide. But plenty of room still remains for 
improvements and innovations. Currently, these initiatives of thee-Health 
program such as an effort to furnish all European citizens with chip-cards 
(Health-Smart Card) for insurance and health data are being implemented. 
Other targets, like the telematic health network, seem more distant. 
"Healthcare best practices in networking" was mentioned as one of the goals L 
for the end of the year 2000. A look at the e-health website under "best 
practice" reveals a collection of scientific programs, databases and 
technologies that are definitely highly innovative but not up to par with the 
kind of data usually expected under the heading "best practice" in medicine. 
Such expectations may include evidence-based guidelines for clinical practice 
for physicians and a similar database for patient use. The programs presented 
have been selected by IST, the Information, Society and Technology program 
of the EU. Even though they are all medicine related, the term "best practice" 
is somewhat misleading since none of them primarily deals with clinical 
aspects. 
i 
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A framework for evidence-based health care in the European 
Union 
The European Commission released a statement on the development of public 
health policy in the European Community in April 1998 with references made 
to evidence-based medicine and best practice. 
A major emphasis within the information strand covering both 
health status and health systems would be placed on best 
practice in health care, i.e. the current best evidence as regards 
the safety, efficacy, effectiveness, and cost-effectiveness of 
different approaches to health promotion, prevention, 
diagnosis, and treatment; for instance the cost-effectiveness of 
screenzng programmes, health education programmes, 
emergency services and new pharmaceutical products. The 
work would aim to promote and bring together activities in the 
Member States in the fields of evidence based medicine, quality 
assurance, and improvement, appropriateness of interventions 
and health technology assessment. Co-ordination of work in 
these fields would be supported and set on a formal footing in 
order to pool the expertise of the centres in the Member States, 
to gather and exchange information, stimulate international 
studies and improve the dissemination offindings.46 
The European Union has begun to outline strategies to address the increasing 
demand for quality health care in the European Union. Demographic changes 
have led to an "over-aging" of the population that is unprecedented in history. 
Age related diseases will increase costs and further strain the already limited 
health care resources. Applicant countries of the former Eastern Bloc will soon 
join the European Union. These countries have even fewer resources and more 
substantial health problems than the existing member states. Thus, 
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improvements in the effectiveness and efficiency of the health systems will 
become increasingly important. 
According to the 1998 statement cited herein, "best practice" leads to an 
overall improvement of health systems. Such an assumption seems logical, but 
to my knowledge, has not been proven through any type of studies. Evidence-
based medicine examines clinical outcomes. Such outcomes must be viewed as 
intermediate outcomes in relation to the entire health system. The inference 
that the advancement of many intermediate outcomes will lead to an 
improvement in the overall performance and outcomes (measured in 
morbidity, mortality, DALY s .... ) of a health system appears to be based on a 
causal chain but without proof, remains a hypothesis. 
How can "best practice" be defined? Originally, this term was used in the 
industrial sectors. There, "best practice" has been used as a process oriented 
concept for achieving improvements in quality, effectiveness, cost-
effectiveness and productive output.47 " Best practice" in health care is also an 
emerging concept and mainly associated with evidence -based medicine. In a 
report to the European Commission about "best practice" and European health 
systems, the authors (Perleth eta!.) take a more comprehensive approach to the 
definition of "best practice", extending beyond quality issues. 
The best way to identify, collect, evaluate, disseminate and 
implement infonnation on, and monitor the outcomes of, health 
sector interventions for patients/population groups and defined 
indications or conditions. The information needs to reflect the 
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best available evidence on: safety, efficacy, effectiveness, cost-
effectiveness, appropriateness, social and ethical values and 
quality of health sector interventions. 48 
Remarkably, the authors have placed social and ethical values on the same 
level as efficacy, effectiveness and cost-effectiveness. This reflects a patient-
oriented policy and meets the frequently expressed critiquethat evidence-based 
medicine and "best practice" give rise to a new form of utilitarian orthodoxy.49 
In the same report to the European Commission, 50 the authors foresee three 
best practice activities that will create the basis for evidence-based health care: 
• Health Technology Assessment (HTA) 
• Evidence -Based Medicine (EBM) 
• Clinical Practice Guidelines (CPG) 
Health Technology Assessment is a systematical approach for examining the 
technical performance, safety, clinical efficacy and effectiveness, cost, cost-
effectiveness, social consequences, legal and ethical aspects of the application 
of a health technology.51 Health Technology Assessment is .not seen as a 
defined set of methods, but as an intention to examine health technologies. 52 
Health Technology Assessment is a crucial part of evidence-based health care, 
but this paper will focus on the other two components: Evidence-Based 
Medicine and Clinical Practice Guidelines. 
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Evidence-based medicine 
As previously mentioned, evidence-based medicine promotes the use of 
scientific evidence to answer clinical questions about the effectiveness of 
clinical interventions and treatments. The feasibility of evidence-based 
medicine for everyday clinical use is limited by various factors. Some of the 
factors occur on a personal and individual level. These include issues such as 
amounts of motivation, interpretation skills, ability to critically appraise 
evidence and simply personal time. Others, like accessibility to databases, take 
place on an infrastructurallevel. 
How could evidence-based medical databases in a European telematic health 
network look? The most rational approach for the European Union would be to 
learn from experience- on both national and international levels. Existing 
databases can be stratified into 3 levels of evidence- based medicine: 
• primary databases containing bibliographic listings of clinical trials 
or studies, reviews, and editorials; 
• secondary databases containing "synthetic studi.es" like systematic 
reviews, meta-analyses, or cost-effectiveness analyses, that are 
products of extensive and systematic literature reviews of primary 
databases; and 
• tertiary databases, condensing primary and secondary evidence-
based data to make the information more comprehensible for 
readers. 
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Examples of primary databases include general databases such as MEDLINE, 
and EMBASE, and specific databases such as AIDSLINE, and PsycLIT. All of 
these databases are bibliographic, medical literature databases. Since problems 
arise from the method of indexing used by some of these databases - an 
indexing that can limit search results, even with extensive search strategies -
users must be aware of retrieval bias. To minimize retrieval bias, the Cochrane 
Collaboration created the Cochrane Controlled Trials Register. This 
bibliographic database with improved indexing also contains additional hand-
searched studies from medical journals around the world. This approach 
increases the availability of non-English studies. Furthermore, it reduces 
publication bias because studies showing no statistically significant results, and 
initially published in languages other than English are rarely translated and 
published in English- language journals. 
At the outset, the European telematic health network would not focus on 
primary databases. Complex search strategies and the enormous amount of 
scientific information associated with primary databases are often too time 
consuming for the individual health care decision-maker. In addition, once the 
Cochrane Controlled Trial register has been completed, an excellent primary 
database will be available that also includes studies concerning the European 
population. In my opinion, the European telematic health network should 
concentrate on the creation and linkage of secondary and tertiary databases 
tools the average physician is most likely to consult. 
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Examples of secondary databases include NICE (National Institute for Clinical 
Excellence) in the UK and the Cochrane Collaboration. These organizations 
mainly feature systematic reviews and meta-analyses- cost-effectiveness 
analyses to a lesser extent. The Cochrane Collaboration enj.:Jys a high 
reputation in the medical community due to its strict methodologies and its 
global network of contributing scientists and physicians. The Cochrane 
Collaboration has been particularly effective in minimizing .~onflicts of interest 
on a national level. NICE, on the other hand, has frequently been accused of 
being used by national committees to promote their own interests 5 3 
An example of a tertiary database is Bandolier. Bandolier is a print and 
Internet journal based at the University of Oxford, UK. It is. considered the 
prime source of evidence-based information for general practitioners in the 
UK. The impetus behind Bandolier is to provide information about the 
effectiveness (or the lack of it) of treatments for healthcare professionals and 
consumers.54 Topics are presented in a clear and user-friendly manner although 
they lack the methodological background information that secondary databases 
like the Cochrane Database of Systematic Reviews offer. 
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A Hypothetical Structure of evidence-based databases. 
As previously mentioned, secondary and tertiary databases probably offer the 
most effective tool to reach the average European health decision maker. To 
insure proper consideration of national priorities in medicine and public health, 
each country could create an Evidence-based Practice Center (EPC) similar to 
those founded by the AHRQ (Agency for Health Care Research and Quality) 
in 1997 in the US. The US centers issue authoritative evidence-reports on high 
priority clinical topics and technologies.55 1 
Additionally, the European EPCs would pursue national databases in the I r 
native languages. Information gained from systematic reviews would have to 
be exchanged and translated by the EPCs. Promoting national health issues 
could be another important tasks of the national EPCs. For example, evidence-
based reports on immunization programs to control Central European 
Encephalitis, a tick -borne disease, are of high public health priority in the 
southern part of Central Europe but of no concern in Scandinavia. 
Primarily, topics should cover the effectiveness of treatments and preventive 
clinical services and health technology assessment. Later the scope could be 
extended to cost-effectiveness. All these databases must be free of charge and 
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readily available to health care decision-makers and consumers via the 
Internet. 
NICE is an example of a free database for patients and physicians. One 
explicitly stated additional function of NICE is clinical audit. NICE is 
supposed to develop tools to monitor the use of particular interventions or the 
care received by patients within the National Health System (NHS) of the UK. 
The necessity of program evaluation is definitely crucial, although I do not 
think that this should be a task of the EPCs. I believe this for two reasons in 
particular. First, it is questionable if an institution that develops and 
implements a program should evaluate itself and the effectiveness of the 
program, thus creating a conflict of interest. Second, I think that the acceptance 
of evidence -based databases is higher if health care decision makers don't 
have the feeling that the adherence to findings is supervised and controlled. 
Numerous activities in health technology assessments, systematic reviews, and 
guideline developments are reported on federal levels within the European 
Union. 56Germany, the Netherlands, and the UK are the avant-garde in these 
fields. Existing federal activities could be incorporated in national EPC 
development. 
A potential, efficient partner for a working-coalition could be the Cochrane 
Collaboration. Founded in 1993, the Cochrane Collaboration is a non-profit 
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worldwide network made up of scientists, physicians, and methodologists 
working for the organization on a volunteer basis. Of the fourteen Cochrane 
Centers worldwide coordinating and organizing reviews, seven are located in 
the European Union. Review groups are responsible for specific topics. Once 
an author has adopted a topic, he/she will continue to monitor new publications 
on the topic to keep the reviews up-to-date. All systematic reviews are peer-
reviewed before they are published. The Cochrane Library consists of 4 
databases: 
• The Cochrane Database of Systematic Reviews 
• The Cochrane Controlled Trials Register 
• The Databases of Abstracts of Reviews of Effectiveness 
• The Cochrane Methodology Database I 
,--The Cochrane Library can be seen as the most important database of 
systematic reviews worldwide. In the nine years of its existence, the Cochrane 
Collaboration has completed 1377 systematic reviews (as of 5/2002).57 In 
comparison, during the three years of the NICE's existence, 5 systematic 
reviews have been completed. 58 
Federal organizations in Europe are highly susceptible to being inefficient due 
to bureaucracy, attempted influence of interest groups and under-funding. In 
my opinion, this poses the main threat to the efficiency of EPCs on national 
levels. A working coalition with the Cochrane Collaboratio;1 could create more 
dynamic. The EPCs should be established as private entities operating on 
federal and private funds. Bandolier offers a positive precedent. While the base 
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of the Bandolier's financing comes from the NHS (National Health System) in 
the UK, sponsors provide additional resources. Industrial sponsorship is only 
accepted though, if the sponsor signs a contract that rules out any control and 
influence over Bandolier's publications. 
Obstacles ~--
With 11 different official languages, the European Union must overcome the 
challenge of establishing evidence-based databases and guidelines that can 
reach health care decision makers of different languages. Where a physician I 
r 
decides to search for medical information is often based on the language the 
database uses. Most physicians prefer to use databases in their native tongues. 
Even when physicians are aware of the existence of evidence-based databases, 
medical English can challenge and limit physicians who do not speak English 
as a native language. Most of the institutions that provide evidence-based 
medicine online in forms of "best practice " databases are currently in English. 
Although most European physicians are fluent in English as a second 
language, medical English with its distinct vocabulary and semantics can be a 
very time consuming obstacle for the non-native speaker. Therefore, the 
acceptance of these resources is rather low. A recent survey under German 
physicians shows that 70 % think that medical English is a barrier to their 
further education. 59 
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However many more possible limiting factors have to be considered. One will 
definitely be the user friendliness of the database. Most health decision makers 
work under time pressure and have some assertive skepticism towards new 
technologies that could consume time. Therefore, the efficiency of an 
evidence-based database will be a crucial factor. Initially, it will be very 
important that implementation is not a static process but a matter of cybernetic 
decision making based on feedback from the target group. hnprovements must 
be derived from needs and must be continually administered to guarantee the 
efficiency of the database and its subsequent acceptance. 
McColl et a!. conducted a survey among general practitioners in the UK to I 
f 
examine attitudes towards evidence- based medicine60. The respondents mainly 
welcomed evidence-based medicine and agreed that its practice improves 
patient care. But the major perceived barrier in practicing evidence-based 
medicine was a lack of personal time. These results agam demonstrate how 
important it is for evidence-based information to be accessible over an 
efficient, user-friendly database to allow users to view the time spent on 
information-research as a valuable investment in patient care. 
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Practice Guidelines 
Practice guidelines can help clinicians make informed decisions that are 
evidence-based and provide effective clinical practice while considering the 
unique situation of the individual patient. Field and Lohr define guidelines as 
being 
systematically developed statements to assist practitioner and 
patient decisions about appropriate health care for specific 
clinical circumstancei1 
On one hand, guidelines assist clinicians in evaluating and reflecting upon their 
own patient management strategies. On the other hand, guidelines can be seen 
as state-of-the-art suggestions to meet information needs and face medical 
problems. In addition, the demand by patients to receive evi.dence- based 
treatment is steadily increasing. 
A study by Gorman found that patients have high expectations of their 
physicians to know the right answer. Expectations such as these act as an 
impetus, encouraging physicians to seek further information62. Guidelines and 
evidence-based reviews can efficiently satisfy this demand for information and 
are far more accessible than research articles as a guide for current best 
practice. 
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Guidelines are ideally based on scientific evidence that is extracted from 
medical databases through systematic searches. Predetermined search criteria 
and predetermined criteria of effectiveness are ways to reduce bias. Selected 
trials or meta-analyses are rated by quality criteria and internal and external 
validity are carefully assessed. The often very heterogeneous evidence must be 
integrated and expert opinion is used to support these decisions. 
The advantage of an evidence-based approach versus an expert -opinion-
based approach is that it provides a clear rationale to defend medical patient 
management and public health policy. Limits of an evidence -based approach 
include the usual shortage of good data - especially for preventive 
interventions where the time lag between interventions and outcomes can be 
very long. Therefore, intermediate outcomes must be used to infer 
effectiveness, which inevitably involves trade-offs. Short- term physiologic 
changes can lead to premature conclusions and an overestimation of the 
effectiveness as long as the overall outcome is not assessed. Therefore 
accepting intermediate outcomes might introduce type I errors, which means 
finding a significant result or difference where there actually is none. 
All in all, synthesizing practice guidelines is a very complex, labor intense 
effort. The U.S. Preventive Service Task Force is an example of a national, 
governmental effort to provide evidence-based guidelines on preventive 
medicine. Teams work on prioritized topics using so-called "analytical 
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frameworks" graphically map out specific linkages in the evidence that must 
be present to be considered effective.63 For example, direct linkages show a 
relationship between the intervention and reduced morbidity or mortality. 
Direct linkages are weighted higher than indirect linkages that show a 
relationship between an intervention and an intermediate outcome. The topic 
team's primarily focus on high -quality evidence if available and may exclude 
low-quality evidence. The process must be well documented and replicable for 
outsiders. This minimizes the danger to cite evidence selectively in support of 
a recommendation. Graded levels of recommendations show where research 
evidence is less conclusive. 
Making recommendations, however, goes beyond reviewing scientific 
evidence. Issues like cost effectiveness, ethical and legal concerns, or societal 
expectations must be considered as well. Historically, the Task Force's main-
focus has been on recommendations that reflect the state of the evidence.64 
This leaves room for decision makers to consider additional factors in their 
process of decision- making. 
As mentioned above, clinical practice guidelines should reflect scientific state-
of-the-art knowledge. Grant et al. looked at articles cited in clinical guidelines 
using bibliometric analyses.65 Their objective was to evaluate the impact of 
research on health and to characterize the papers cited on clinical guidelines. 
An interesting aspect of the results was a characteristic coined by the authors 
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as" knowledge cycle time". This is the time between the publication of a paper 
and its citation in a guideline. The median knowledge cycle time for all 15 
guidelines was 8 years. In other words, it takes a median of 8 years for 
scientific evidence to find its way into clinical practice guidelines. This may be 
a problem in an active area of study, like HIV, where the half-life of 
knowledge is very short. The majority of articles cited were high in quality and 
originally published in level! (clinical observation) or level2 (clinical mix) 
research journals. Nevertheless, 15% of the cited papers did not have a 
research level. 
Dissemination and Acceptance of Guidelines I 
The success of a telematic health network in the European Union will rise and 
fall with the acceptance of practice guidelines and evidence-based databases by 
clinicians and health care decision makers. 
Pathman D., Kourad T. et al. have developed an "Awareness-to-Adherence 
Model" to outline the steps of physicians to clinical guideline compliance66. 
The article explores the cognitive and behavioral steps that physicians take 
when accepting and using clinical guidelines. They postulate that there are four 
sequential steps that physicians make as they comply with guidelines. 
(Awareness-Agreement-Adoption-Adherence) First, they must become aware 
of the guideline, then intellectually agree with it, then decide to adopt it in 
their clinical practice and then adhere it at appropriate times. At each of the 
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four steps, progression can stop for various reasons. They also mention that in 
times when clinical practice is increasingly monitored, agreement as a factor 
might not always exist when a guideline is still adopted and adhered. 
Once a health decision maker consults guidelines, there are still features of the 
guidelines themselves that will be critically appraised and could be seen as 
possible obstacles. The most important attributes determining guideline 
acceptance are scientific validity and credibility. Guidelines must be based on 
available scientific evidence accepted among respected authorities in the field. 
Another factor is the degree of generalizability and preciseness of definitions 
within the recommendations. Theoretical acceptance of guidelines, however, 
does not necessarily translate into implementation of them in practice. A Dutch 
observational study looked at attributes of clinical practice guidelines that 
influence the use of guidelines in clinical practice. 67 Three reasons were cited 
for the failure to comply with guidelines. 
• The recommendation is controversial and not compatible 
with current values 
• The recommendation is vague and not precisely defined 
• The recommendation demands change of fixed routines 
Generally, recommendations based on evidence were used more frequently 
than those that were not evidence-based. Also, effects on daily work influenced 
the use in clinical practice. 
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Another important aspect is the validity of guidelines. Practice guidelines need 
to be up-to-date and present current scientific knowledge to be useful for 
clinical practice. The National Guidelines Clearinghouse only accepts 
guidelines in their database that have been developed or revised within 3 ye<!fs. 
Shekelle et a!. evaluated 17 clinical practice guidelines in 2001 published by 
the US Agency for Healthcare Research and Quality (AHRQ) between 1990 
and 1996.68 The results show that 7 guidelines needed major updates, 6 minor 
updates and only 3 were still valid. A Kaplan-Meier survival analysis 
suggested that the estimated time of "survival" for 50 % of all guidelines is 
5.8 years (95 % CI (5.0-6.6)). The point at which 90% of all guidelines were 
still valid was at 3.8 years. Shekelle concludes that, as a general rule, 
guidelines should be revised every 3 years. 
Examples of institutions that provide clinical practice guidelines include NICE 
in the UK and the National Guideline Clearinghouse in the US. NICE 
concludes systematic reviews with clinical practice guidelines. On the other 
hand, the National Guideline Clearinghouse provides comp,rehensive databases 
of evidence-based clinical practice guidelines. The National Guideline 
Clearinghouse is a public Internet forum sponsored by the AHRQ (Agency for 
Healthcare Research and Quality), The American Medical Association (AMA) 
and the American Association of Health Plans (AAHP). Guidelines presented 
are not only the ones developed by the AHRQ, but also other guidelines 
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developed by medical specialty associations (e.g. American Heart 
Association). All guidelines have to be revised at least every 3 years otherwise 
they will be dropped from the database. 
The National Guideline Clearinghouse is by far the most comprehensive 
database of clinical practice guidelines that exits. An important utility is the 
possibility to compare two or more guidelines of the same topic and review 
abstracts about the guideline development. As mentioned above, guideline 
development is a complex issue, the comparison of guidelines from different 
sources could reveal different recommendations and enables the reader to 
critically assess different aspects. I 
\ 
A "European Guideline Clearinghouse" could be centralized and supplied with 
inputs from national medical specialty associations. Again, providing 
guidelines in the different national languages will be a crucial factor to 
guarantee the acceptance and the success of the Clearinghc.Jse. 
Nevertheless, there are justified concerns among practitioners about the use of 
guidelines that go beyond scientific validity and the change of routines. Some 
fear hidden motives influencing clinical practice guidelines, like costs. 
Therefore, cost containment should always be explicit. This is especially true 
in Europe where bureaucratic interference on political grounds occurs on a 
daily basis. Therefore, the independence of a panel working on guidelines must 
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be guaranteed. Punitive measures or liability issues againsi tbose who deviate 
from guidelines are also reasons for concern. 
Others criticize the lack of psychosocial aspects of medical practice m 
guidelines. Evidence-based medicine is clearly focused on quantitative 
research. Guidelines can only be a part of tbe clinical decision making process. 
Individual psychosocial aspects, empathy and social expectations are equally 
important variables and must be part of this process. Good medical practice 
depends on more than scientific evidence. 
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Outline of an evaluation program 
Evaluation is the base for improved decision-making. Organizations can learn 
from information gained through evaluation and these inputs can foster a 
process called "cybernetic decision-making"- transforming a program from a 
static procedure to an ongoing process of improvement. Senge views this from 
an organizational level and calls it" generative learning''. 
Adaptive learning [survival learning] is important-indeed 
necessary. But for a learning organization, "adaptive learning" 
must be joined by "generative learning", learning that 
h . 69 en ances our capaczty to create. 
Evaluation assesses if a given program produces the desired impact in an 
effective and efficient manner. By identifying obstacles, and factors that 
threaten or reduce the success of a program, evaluation provides the necessary 
information for optimization. Speaking in terms of the telematic health 
network and evidence-based databases, evaluations should identify why health 
care providers are not accepting, using or applying information contained in 
the health network Evaluation results can then be used to improve the 
program and adapt it to the needs of the health care providers and subsequently 
increases the acceptance. In the long run, evaluations will determine whether 
or not the telematic health network has been successful in has achieving its 
goal: improved quality of health care. 
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Levels of evaluation 
The effectiveness, efficiency, impact and sustainability of a program will 
largely depend on whether or not health care providers accept the program. 
The goal is well defined - an improvement of health care and health outcomes. 
The question remains, however, how much these factors can be improved by 
evidence-based medicine. Again, the success or failure will depend on how 
many practitioners consult an available database, how frequently they do so 
and how they utilize the information in their decision-making process. 
Acceptance will also depend on the user-friendliness of the network - if it is 
quick, easy and convenient and provides up-to-date, accurate information. 
To optimize the decisive factors, cybernetic decision-making will be crucial in 
increasing the acceptance of a telematic health network since cybernetic 
decision~making is the only way to quickly and efficiently adapt the program 
to the needs of health care professionals - a group characterized by an assertive 
skepticism towards any type of new technologies with time consuming 
potential. 
Ongoing evaluations and cybernetic decision-making will lead to 
improvements that will subsequently create a telematic health network that is 
considered "state of the art". As previously mentioned, the system must 
include the highest standard of evidence-based medicine data available in all 
national languages of the European Union. A telematic health network will not 
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only depend upon the acceptance of the physicians, but also on the availability 
of vital resources, like reliable Internet connections and phone lines, still a 
limiting factor in some southern European countries. Both aspects have to be 
considered in an evaluation process. 
Outlines of evaluation 
The process of evaluation consists of 2 steps- formative and summative 
evaluation. 
and will be crucial to provide the necessary input for cybernetic decision - I Formative evaluation refers to activities associated with the ongoing program 
making. Repeated surveys among the target population and monitoring of the 
program will be the base for adjustments to raise the acceptance of the 
program. Formative evaluation, however, will have to use various perspectives, 
for example, the physician perspective on how easy and convenient the 
program is to use; the patient perspective on how the patients feel about the 
treatments when informed that they have stemmed from evidence-based 
medicine for clinical decisions. Will patients come to expect evidence-based 
treatments? 
Summative evaluation refers to the goals of a program and would entail a long-
term project since it will probably take years for European databases and 
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guidelines to become widely accepted and used as well as adjusted to all needs. 
Summative evaluation will assess if the impact of the program has attained the 
explicit objective of improving health care and health outcomes for all 
European citizens. 
An implicit objective not mentioned by the European Commission in writing, 
is a reduction of health care costs. Health budgets have been strained for years 
and savings would be welcome. The reason for keeping this objective implicit 
lies in ideological backgrounds. A large part of the European governments are 
social-democratic - individual benefits (health, education. quality of life) are 
valued higher than monetary gains. 
Methods of evaluation 
Initially, formative evaluation will be the focus of a progrmn to provide a base 
for cybernetic decision-making during the ongoing implementation process of 
the network. In my opinion three main methods of evaluation could be useful 
in evaluating the implementation of evidence-based databases: 
• Surveys - descriptive surveys providing information about the status quo 
of the acceptance and the use of evidence-based practice; analytic surveys 
providing an insight into the perceived obstacles and barriers for the use of 
EBM. 
• Monitoring -mainly reflecting the progress of the program and comparing 
operation and intermediate results with expectations. Monitoring will also 
play a role in the summative evaluation. 
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• Trend analysis - focusing more on the outcome of the program including 
the acceptance and use of an evidence-based telematic health network. 
Surveys can be used in conjunction with monitoring and trend analysis to 
provide a more thorough picture of the program. 
Surveys 
Surveys can be a valuable tool for evaluating implementations of a telematic 
health system in the European Union. Preliminary surveys should be used to 
gather information before the implementation process. Ideally, a descriptive 
survey could be used before the implementation to provide a baseline of the 
extent of the current use of evidence-based practice. A survey could provide 
information about attitudes and behavioral aspects regarding the use of 
guidelines in particular and evidence-based medicine in general. 
Questionnaires could be conducted via postal mail and the Llternet. 
Questionnaires over the Internet have the advantage of saving valuable time 
and money by making information available faster and for less money. The 
limiting factor and a possible risk of selection bias, however, would be that 
physicians who use email for communication are also more likely to use the 
internet as a tool to gather medical information - in other words, those who 
would respond to an internet survey are already using online tools and 
therefore may have a more positive attitude towards a European-wide telematic 
60 
L 
L 
health network. Therefore, if average European physicians are the defined 
target group, surveys distributed through the postal mail may remain the most 
reliable method to reach them. 
National medical associations could provide a pool of physician addresses. 
Researchers could then perform a random selection of a col',ort from these 
addresses. However, physicians from all 15 nations must be represented in the 
survey in order to consider any national differences. Questionnaires have to be 
written in the respective native languages and all versions must be consistent 
and unifonrJy understood70• The preliminary questionnaire must cover a 
variety of different aspects. 
• Tracers must be defined beforehand and assessed at baseline. Tracer 
Condition Methodology and Trend Analysis can be conducted later on in 
the evaluation process on common clinical conditions. Such conditions 
must have enough evidence available about the most effective treatment 
methods. Such conditions may include hypertension and/or diabetes. 
• General attitudes of physicians towards EBM can be explored. 
• Perceived obstacles for the use of the evidence-based databases and clinical 
practice guidelines should be assessed. 
• The current use of evidence-based medicine before the actual 
implementation of the program can be examined. The Evidence- Based 
Medicine Working Group developed a hierarchy of so called "preprocessed 
evidence"71 . The authors have identified four groups of such evidence: 
l) Studies 
2) Systematic Reviews 
3) Synopsis 
4) Systems (e.g. guidelines ) 
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This hierarchy could be used as a framework for preferences in evidence-
based medicine. This would also provide a base to see if shifts in preferences 
occur over time. 
After successful implementation of the network, annual surveys could be 
conducted to reveal changes in attitudes and perceived obstacles. As stated 
earlier, Tracer Condition Methodology could monitor changes in treatment 
patterns. Repeated surveys would also supply data for Trend Analysis. 
As mentioned before, Pathman, Konrad eta!. have developed an Awareness-
I to- Adherence Model of the steps to Clinical Guideline Compliance. 72 This model could be very useful when undertaking analytical surveys on why 
physicians do or do not accept and use guidelines. Their model reflects the 
behavioral and cognitive steps that physicians take to eventually accept and 
adhere to guidelines. As previously mentioned the authors outline four 
principal steps, or significant "A"s, in this process: 
o the Awareness of the guideline; 
o the intellectual Agreement with this guideline; 
o the Adoption of the guideline; 
• the Adherence to the guideline at appropriate times; 
At each one of these steps, specific factors and influences can prevent further 
progression to the next step. This means that surveys following 
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implementation should be more thorough than those before it. They should 
also specifically address the four points of the Awareness-to-Adherence Model 
(Awareness- Agreement-Adoption-Adherence). This permits barriers and 
obstacles to be identified and the program to be adjusted accordingly. 
While information is gathered on target groups, the evaluation process should 
also investigate patient perspectives through interviews of randomly selected 
patients. The cohort should reflect the national heterogeneity of the European 
Union to reflect the differences in values, mentalities and preferences of people 
from 15 different nations. Patient interviews should focus on the preferences 
and expectations of patients when the patients visit a physician. The amount of I empathy a physician displays to a patient combined with the length of time of a 
consultation may conceivably rank higher in importance for patients than the 
latest scientific treatments. Patient satisfaction is definitely a highly important 
intermediate outcome. Discrepancies between patients and health care 
providers on how quality health care is defined can have a detrimental effect 
on the patient-physician relationship. The good of the patient must remain 
more important than guideline adherence. 
Monitoring 
Monitoring will mainly focus on operational aspects of the program. This will 
start if the implementation process is able to follow a given timetable. A 
review of the fulfillment of the technical requirements will be necessary to 
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ensure the smooth implementation of the network in all participating countries. 
One of the goals of e-Europe is to bring all citizens online. Such a goal can 
only be reached if national governments and private companies provide the 
infrastructure necessary in the form of up-to-date reliable telecommunication 
networks. Technical difficulties can severely undermine the success and 
acceptance of a European telematic health network. Surveys can be an 
additional tool to provide valuable information on any technical difficulties 
facing health care providers. 
Knowledge gained from monitoring must be used to change and improve the 
' i 
I process. One way to assess acceptance and the extent of implementation would be to monitor the amount of hits on and time spend at the website. In 
T 
addition, inputs into the program such as personnel resources, finances and 
information for the target group on the program should also. be monitored. 
Limitations on monitoring are not the only factors possibly influencing the 
operation of the program. Nevertheless, it is important to initially identify the 
main factors of limitation so that these can be adjusted during the monitoring 
process. 
Finally, monitoring will play an important role in the summative evaluation of 
the program. An improvement in the health status of the European citizens can 
be seen as the expectation for program's overall outcome. Since health status 
per se is hard to define and measure, monitoring of proxy measures like 
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morbidity and mortality will be an appropriate method of assessing health 
statns improvements. Disability adjusted life years (DALYs) for diseases used 
in the Tracer Condition Methodology could be particularly interesting. A direct 
relationship between the use of evidence-based medicine and a possible 
reduction of lost DALY s could be shown on both the societal level and the 
disease-subpopulation level. However, no long-term studies exist proving 
evidence-based health care actually improves health outcomes because 
evidence-based medicine is still a relatively young concept. Changes in health 
outcomes are best assessed with prospective observational studies that follow a 
cohort over many years. One method to evaluate this would be through trend 
analysis. 
Trend Analysis 
Trend analysis is an evaluation tool that focuses on outcomes and evaluates if a 
program is responsible for changes in outcomes. Defined performance 
indicators are examined over a period. Data for trend analysis can be retrieved 
from surveys or monitoring. Possible dependent variables could be treatments 
for conditions previously defined for Tracer Condition Methodology; hits on 
the website; length of time spent on the website; attitudes towards evidence-
based medicine; perceived barriers and, in the long run, changes in morbidity 
and mortality. 
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The task of Trend Analysis is to show that changes of the dependent variable 
over time are truly due to the implementation of the program. Possible sources 
of error, like regression to the mean or miscounting and reactiveness must be 
considered. Miscounting and reactiveness can stem from the data used from 
surveys. Selection bias in surveys may occur if users of evidence-based 
databases are a group that is more motivated to return surveys about these 
databases. 
, 
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Other factors that can possibly influence the outcome variable also must be 
considered. In the case of the telematic health network, factors like the 
awareness of a database, the access to Internet, the age and the nationality of I the physician, and many more can possibly confound the statistical 
significance of the acceptance as a dependent variable. Multivariate regression 
can show if there is a statistically significant change while controlling for other 
explanations for changes than the program itself. For this tc work, however, 
the time span of the observation must extend long enough to overcome the 
intermediate results of an evidence- based database that may be time lagged. 
Stratified analysis can provide valuable information about each country. 
National differences in attitudes, health systems or infrastructures can lead to 
different outcomes and might require adjustments and improvements to the 
program tailored to the specific needs of physicians within 'hat particular 
country. 
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Sampling 
To take the heterogeneity of the European Union into consideration, samples 
from each nation must be drawn. This stratified sampling w1ll increase the 
precision of the results. Just as with surveys, national medical associations can 
provide pools of physician addresses. Random sampling is critical to guarantee 
the external validity of results and minimize selection bias. The process of 
administrating surveys must include the weighing of the advantages and L 
disadvantages of repeated random sampling. Using the same cohort for 
repeated surveys could provide valuable information for trend analysis, l 
I especially if combined with analytic surveys about perceived barriers towards evidence based medicine. On the other hand, repeated random sampling would 
' 
reduce ascertainment bias. Through the preliminary survey, the participating 
physicians may become aware of the program and its intentions. By retaining 
the same cohort for repeated surveys, participants may overestimate their 
amount of evidence-based practice, unconsciously trying to fulfill 
expectations. Information on patient conditions and treatments submitted by 
physicians to health insurance companies could provide information on 
evidence-based health care that is more reliable. However, privacy concerns in 
this matter remain a justified public issue. 
Low Response rates can impose major problems on any surveys. Nonresponse 
refers to the unwillingness or the inability of people selected for the sample to 
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cooperate in answering a questionnaire.73 In their book "Evaluation and 
Decision Making for Health Services" Veney J. and Kaluzny A. state: 
.. . nonresponse remains a problem because it is not reasonable to assume that 
those who fail to respond to a questionnaire or interview are essentially no 
different from those who do respond in regard to the subject of the survey. 74 
People willing to respond usually perceive the program as important. Generally 
it is crucial to make every possible effort to collect data from a high proportion 
of the sample. The authors conclude: 
Generally, however, it is better to accept a smaller sample with a lower 
proportion of nonresponse than a larger sample with a larger proportion of 
nonresponse. 
Cost-effectiveness, Cost-benefit, Cost-utility analysis 
Eventually the public will also demand results that are less abstract than 
DALYs and QUALYs. Cost-effectiveness analysis is the classical approach 
used in evidence-based medicine to give results of trials a cost perspective and 
is often used as an example for the success of evidence-based medicine. 
However, in the context of a population, cost-effectiveness of the treatment for 
a single patient can only be seen as an intermediate outcome. To assess the 
overall benefit for a population some kind of utility has to be applied. Cost-
utility analysis brings changes in defined utilities like DALY s or QUAL Y s for 
a whole population or a diseased-subpopulation into play. Cost -benefit analysis 
would put a Euro amount on a chosen utility. Both analyses discount the 
present value when a measure of utility is received in the future.75 
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Threats to validity 
Cost-utility and cost-benefit analyses will be the decisive results of summative 
evaluation in determining the success or failure of a European telematic health 
care system. Threats to validity could mainly stem from attempts of political 
influence on the results. E-health is based on a political initiative of the 
European Commission. Politicians are responsible for the program and the 
output of any evaluation process will become part of the political discussions 
in Brussels and the EU in general. Considering the political culture in Europe, 
the attempt of politically influencing the results of a summative evaluation 
report could be a matter of concern. Financial independence; participation by 
experts in the field of evaluation; and both public and media scrutiny should 
guarantee a minimization of this threat. 
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Summary and Discussion 
Although no official details on the telematic health network and evidence-
based databases have been released yet, the European Union has outlined the 
course of its health care - evidence-based medicine. The European Union has 
recognized the Zeitgeist of modern clinical medicine and is working to 
facilitate the practice of evidence based-health care by starting political 
initiatives like e-Health. In acknowledging the boundaries of evidence-based 
medicine, the European Union has also remained conscious of the 
philosophical and ideological influences on European programs - most of them 
culturally based - and important to the implementation of any successful 
program. 
In a report on evidence-based health care, the European Union equated the 
classic attributes of evidence-based medicine like effectiveness, efficiency, 
efficacy, and cost-effectiveness to humanistic values like appropriateness, 
social and ethical aspects, and patient values. The design of this equation is an 
important step in the union of cultures deeply suspicious of and critical 
towards any kind of social Darwinism and the rise of a new utilitarian 
orthodoxy.76" In Europe, evidence-based health care must be socially inclusive 
and must guarantee the best available quality of care for every single citizen to 
be politically successful. 
70 
Health care is conceived as a basic right for each citizen equal to the concepts 
of free education and freedom to vote. An unwritten social contract exists 
between the generations that forbids leaving the weak and underprivileged 
without sufficient health care, one of the main differences to the U.S., where 
many people view health care as a utility, a benefit rather than a basic right, 
and one that can only be acquired through hard work. This leads to the 
common causal fallacy that people who don't have health insurance either 
don't want it or don't work hard enough to deserve it. For Europeans this state 
of mind is hard to comprehend, too deeply rooted is a general altruistic, social 
conscious. It is commonly thought in Europe that a society's greatness is not 
measured in economic wealth but rather its treatment of its weakest members. 
Therefore the emphasis of evidence-based health care must be on the 
improvement of the quality of care. Costs are generally seen as important but 
remain secondary. The European Union reflects this sentiment in not 
mentioning cost-reduction as an explicit objective. That it is an implicit 
objective can be deducted from the political reality of increasing health care 
costs. 
What benefits could public health gain from evidence-based medicine and 
evidence-based health care? As mentioned above, evidence-based medicine 
primarily improves the quality of care on an individual level through 
optimizing the process of clinical decision-making through the use of 
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scientific evidence as a base. An extrapolation of these individual benefits will 
lead to health improvements of the general population. One such example is 
the use of beta-blockers after myocardial infarction. 
A great potential for public health lies in the use of evidence-based medicine in 
preventive medicine. On the one hand, some screening programs can be very 
costly but equally beneficial such as the one targeting the reduction of cervical 
cancer deaths through PAP-smears. On the other hand, other screening 
programs either lack effectiveness when scientific evidence is systematically 
assessed or the benefits fail to outweigh the risks. This happened in the 
screening for adolescent idiopathic scoliosis in schools - widely practiced even 
mandatory in some states. Current evidence suggests that the screening 
methods used had low sensitivity and that the natural course of the disease 
often was not progressing and more harm than good came from the resulting 
therapies. The United States Preventive Services Task Force has not found 
sufficient scientific evidence to support school screening fer adolescent 
idiopathic scoliosis and does not recommend school screenings for adolescent 
idiopathic scoliosis.77 
A similar debate about breast cancer screening with mammography was 
initiated recently by findings of Olsen and Gotzsche, who critically assessed 
the methodologies of studies supporting breast cancer screening with 
mammography.78 
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These are just a few examples of how evidence-based medicine can help to 
assess the effectiveness of interventions. In a world of limited resources, this 
information is important to focus on interventions with proven effectiveness. 
From a public health point of view, an allocation of money following the 
rationale of evidence -based findings in preventive medicine will lead to 
maximizing health benefits for larger populations since resources are limited. 
The challenge to implement a network that links 15 different health care 
systems and provides evidence-based medical databases for health care 
decision makers with different languages and backgrounds is certainly great. 
Various factors have to be considered to guarantee the acceptance by the target 
groups (e.g. databases in the native languages). A lot can be learned from 
already existing databases like the Cochrane Database of Systematic Reviews 
or the National Guideline Clearinghouse. The UK is certainly the most 
advanced nation worldwide in regards to evidence-based medicine and could 
play an important leadership role. 
To attain the goals outlined by the European Union e-Health initiative, I 
propose the creation of Evidence-Based Practice Centers (EPCs) and a 
European Guideline Clearinghouse to function as the building blocks for an 
evidence-based network. The EPCs should be represented in each nation to 
emphasize national public health priorities and to provide databases in the 
L 
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national languages. These databases would be readily accessible over the 
internet free of charge. The EPCs must be coordinated to facilitate tbe 
exchange of information amongst them. The European Guideline 
Clearinghouse should serve as a forum for various guidelines of different 
associations. These guidelines will probably not all be evidence-based. The 
main task of a European Guideline Clearinghouse will be to offer the 
opportunity for health care decision makers to compare various guidelines on 
the same topic. 
Crucial to the continued success of such a huge undertaking and running 
parallel to its implementation is an ongoing evaluation of the program. This 
will provide the base for cybernetic decision-making, using information gained 
from the evaluation as feed-back to improve the program. Surveys, Tracer 
Condition Methodology, Monitoring and Trend Analysis are some methods of 
evaluation that can be utilized to achieve this goal. 
Again, the challenge is unique. In hindsight, the mere creation of a political 
union, a common currency and a European spirit amongst historically feuding 
nations was a colossal undertaking. The challenge is indeed unique, but in 
contrast, just another steppingstone. 
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Appendix 
Methodology 
To find relevant articles I searched Medline using "evidence-based medicine 
and European Union", "health policy and European Union", "practice 
guidelines and European Union", "evidence- based medicine and health 
policy", "evidence-based medicine and information technologies" as 
keywords. 
The search was confined to articles published between 1997 and 2002. 
Three hundred and forty-five articles were found. Twenty-one of these related 
to the topic concerned. The main exclusion criteria included subject matter and 
language: 
• orientation of topic was too clinical; 
• articles printed in languages other than English or German. 
The same keywords were used to search the Cordis library of the European 
Union. Two additional articles were found. Furthermore, the archives ofthe 
European Commission have five documents related to the topic. 
An electronic search of the British Medical Journal produced three more 
articles and one more was found in Health Policy. 
I used the official publications of the European Union to draw a framework of 
the program. I submitted a request for more information about evidence-based 
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medicine and the implementation of a future telematic health network to the 
information service of e-health. The reply stated that there are no further 
documents available at this time and that evidence-based databases in Europe 
are currently confined to national levels (e.g. NICE in the UK). In addition, a 
different request to Europe-direct was made. They suggested I consult the 
website of the Directorate General for Information Society, where I retrieved 
some general information about e-Europe. Furthermore I contacted two of the 
authors (Elke Jakubowsky, Matthias Perleth) cited in the official publication 
for the European Commission, " Best Practice": State of the art and 
perspectives in the EU for improving the effectiveness and efficiency of 
European health systems." 
All additional articles retrieved were used for background information and 
mainly identified from references of other articles. 
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